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Abstract 
Aims: Prolonged-release implantable and depot injection formulations of buprenorphine are 
very recent developments in the treatment of opioid use disorder. Such formulations remove 
the need for daily dosing and provide patients with sustained concentrations of buprenorphine 
over a period of weeks or months. We explored opioid users’ personal willingness to receive 
prolonged-release buprenorphine depot injections and factors influencing their interest.  
Methods: The study took place in London during 2018, before depot buprenorphine was 
licensed for use in Europe. Thirty-six face-to-face, semi-structured qualitative interviews were 
conducted with people who were: i) using heroin daily and not receiving any treatment for 
opioid use (n=12); or ii) prescribed daily oral buprenorphine (n=12); or iii) prescribed daily oral 
methadone (n=12). Participants were asked about their willingness to receive depot 
buprenorphine and were encouraged to discuss factors that might alter their opinions. 
Interview data were analysed following the stages of Iterative Categorization.  
Findings: Participants expressed a high level of willingness to receive depot buprenorphine. 
Their views were influenced both positively and negatively by six key features of depot 
buprenorphine: i) reduced contact with pharmacies and drug treatment services; ii) impact on 
illicit drug use and recovery; iii) the perceived effectiveness of depot buprenorphine; iv) the 
duration and dosage of depot buprenorphine injections; v) clinical administration of the depot 
buprenorphine injection; and vi) potential for side effects associated with the depot 
buprenorphine injection. 
Conclusions: Willingness to receive a given medication is complex, individual and 
changeable. Opioid users seem likely to welcome greater choice and flexibility in respect of 
opioid agonist medications and appear more likely to accept and adhere to depot 
buprenorphine if it enables them to reduce their illicit drug use and facilitates their recovery. 
Research is now needed to assess whether patients’ reported willingness to receive depot 
buprenorphine translates into actual uptake and adherence. 
Keywords: Buprenorphine; depot injection; extended-release; opioid agonist treatment; 
prolonged-release; qualitative   
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Abbreviations 
Opioid use disorder (OUD) 
Opioid agonist treatment (OAT) 
 
 
Highlights 
 Qualitative interviews explored opioid users’ willingness to receive prolonged-release 
buprenorphine 
 Opioid users both in and out of treatment expressed interest in receiving depot 
buprenorphine  
 Six key features affected interest in receiving depot buprenorphine 
 Opioid users wanted more information to improve their decision-making 
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5 
Opioid users’ willingness to receive prolonged-release buprenorphine depot injections 
for opioid use disorder 
 
 
1. Introduction 
Opioid use disorder (OUD) affects millions of people worldwide (EMCDDA, 2017; United 
Nations, 2018), with detrimental health and social consequences including premature 
mortality, opioid-related overdose, infectious disease transmission, and crime (Rudd et al., 
2016). Pharmacotherapies for OUD commonly include the prescription of opioid agonists (e.g. 
methadone) or partial agonists (e.g. buprenorphine) (Clinical Guidelines on Drug Misuse and 
Dependence (Update) 2017; NIDA, 2018a; Stotts, Dodrill & Kosten, 2009). The antagonist 
naltrexone can also be considered when a person is opioid-free in order to support abstinence 
and prevent relapse.  
 
In England, treatment for OUD includes the use of methadone and buprenorphine. Commonly 
prescribed through primary care and specialist addiction treatment services at no cost to the 
patient, consumption is usually supervised for a length of time appropriate to an individual’s 
needs and risks (Clinical Guidelines on Drug Misuse and Dependence (Update) 2017). 
Methadone and buprenorphine are typically prescribed in oral form, and for daily 
administration until stability established. Whilst naltrexone is available orally, it is rarely 
prescribed, often due to a lack of interest from patients and issues with adherence (Clinical 
Guidelines on Drug Misuse and Dependence (Update) 2017).  
 
Evidence from numerous randomized controlled trials and observational studies confirms that 
opioid agonist treatment (OAT) is effective in reducing opioid use, overdose, the risk of 
infectious disease transmission, and drug-related criminal behaviour (Bell, 2012; NIDA, 
2018b; The American Society of Addiction Medicine, 2013). Attending a clinic to receive OAT 
also helps to provide structure to people’s lives, increases access to other therapies and can 
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6 
be a source of psychosocial support (Clinical Guidelines on Drug Misuse and Dependence 
(Update) 2017; NIDA, 2018b). Despite this, drugs such as methadone and buprenorphine 
have known negative side effects which include physical dependence (Brunton, Knollmann & 
Hilal-Dandan, 2017; Itzoe & Guarniei, 2017). In some countries, OAT remains controversial, 
politically divisive and disliked, even amongst people who use it (Neale, 2013). This constitutes 
a major obstacle in the treatment of OUD given that uptake and adherence are both likely to 
be poor if patients have negative views and expectations about the medications being offered 
to them. 
 
Over the years, oral methadone has been the most extensively explored OAT from the patient 
perspective. Some people prescribed oral methadone have repeatedly described it as a 
stigmatizing, restrictive and punitive treatment (Crawford, 2013; Harris & McElrath, 2012; 
Radcliffe & Parkes, 2013; Strike et al., 2013). Indeed, patients have likened it to a form of 
social control because it can tie them to strict medication-related rules and monitoring 
systems, such as urinalysis and daily attendance at services (Chandler et al., 2013; Crawford, 
2013; Neale, 2013; Strike et al., 2013; Treloar & valentine, 2013). Studies have compared 
patients’ views of oral methadone with oral buprenorphine (Hill et al., 2015; Kelly et al., 2012; 
Schwartz et al., 2008; White et al., 2007). However, findings from this research have been 
inconsistent and inconclusive; for example, there is evidence that patients prefer methadone 
on some criteria and buprenorphine on others (White et al., 2007).  
 
Oral (sublingual) buprenorphine lasts around 24–60 hours. As a partial agonist, buprenorphine 
activates the mu-opioid receptors in the brain, but to a lesser extent than full opioid agonists 
(Walsh & Eissenberg, 2003). In so doing, it latches onto opioid receptors with high receptor 
affinity, and reduces or ‘blocks’ the rewarding effects of illicit opioid use (Barnwal et al., 2017; 
Walsh & Eissenberg, 2003). In the UK, daily supervised dosing is recommended and 
sometimes required by regulators or treating clinicians, at least until good adherence is 
established. After which time, supervised dosing should be reduced or stopped providing that 
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7 
stability is not jeopardised (Clinical Guidelines on Drug Misuse and Dependence (Update) 
2017). Nonetheless, as with oral methadone, the burden and perceived stigma of having to 
constantly attend services can undermine patient satisfaction and compliance (Barnwal et al., 
2017; Neale et al., 2018a). Further, there is evidence that patients sometimes forget or choose 
to miss oral buprenorphine doses; divert, snort or inject the tablets; ‘misuse’ the medication in 
other ways; or drop out of treatment prematurely and then return to illicit opioid use (Awgu, 
Magura & Rosenblum, 2010; Fareed et al., 2014; Itzoe & Guarniei, 2017; Middleton et al., 
2011; Rosenthal & Goradia, 2017; Sordo et al., 2017).  
 
Poor and non-adherence to oral medications have been important drivers behind the 
development of prolonged-release (also known as extended-release) implantable and depot 
injection formulations for OUD (Compton & Volkow, 2016; Hegde, Singh & Sarkar, 2013; 
Rosenthal & Goradia, 2017; Sigmon & Bigelow, 2016). These new formulations remove the 
need for daily dosing and provide patients with sustained concentrations of medication over a 
period of weeks or months. Even though injectable and implantable formulations of other OUD 
medications (e.g. naltrexone) have been developed and are available in other countries, no 
such licensed products have been introduced in the United Kingdom (UK).  
 
Since 2016, various prolonged-release buprenorphine products have been licensed. First, the 
United States (US) Food and Drug Administration (FDA) approved Probuphine® (Titan 
Pharmaceuticals, San Francisco and Braeburn Pharmaceuticals, Inc. Princeton, NJ, USA), a 
6-month buprenorphine sub-dermal implant (Barnwal et al., 2017; Sigmon & Bigelow, 2016; 
Voelker, 2016). The FDA then approved SublocadeTM (investigational name RBP-6000) 
(Indivior, Richmond, VA, USA), a monthly subcutaneous depot buprenorphine (Lorman, 
2018). In addition, European Commission and the Australian Therapeutic Goods 
Administration approved Buvidal® (investigational name CAM2038) (Camurus AB, Lund, 
Sweden), a weekly and monthly subcutaneous injection (Camurus AB, 2018a, 2018b). In 
December 2018, the FDA also issued tentative approval of weekly and monthly Brixadi™ (the 
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8 
same CAM2038 product approved in Europe as Buvidal) (Braeburn, Camurus’ US partner) 
(Camurus AB, 2018c). Most recently (April 2019) the European Medicines Agency (EMA) 
Committee for Medicinal Products for Human Use (CHMP) recommended the granting of a 
marketing authorisation for the buprenorphine implant, Sixmo, the brand name for Probuphine 
in the European Union (EMA, 2019). 
 
The safety and efficacy of buprenorphine implants have been reported (Ling et al., 2010; 
Rosenthal et al., 2013). Although research into depot buprenorphine injections is still relatively 
new (Albayaty et al., 2017; Haasen, Linden & Tiberg, 2017; Haight et al., 2018; Nasser et al., 
2016; Walsh et al., 2017), findings indicate promising results regarding its therapeutic 
effectiveness and tolerability (Lofwall et al., 2018). Indeed, the safety profile of depot 
buprenorphine appears generally consistent with that of oral buprenorphine, apart from some 
mild-to-moderate injection-site reactions (Haight et al., 2018; Lofwall et al., 2018). In terms of 
patient perspectives, a focus group study (Neale et al., 2018a, 2018b) and a survey (Gilman 
et al., 2018), both conducted with people with a history of opioid use in the UK shortly before 
prolonged-release buprenorphine was licensed, found that participants liked the anticipated 
convenience, reduced stigma, and opportunity to live more ‘normally’ which they believed 
prolonged-release OAT would offer. Nonetheless, the focus group participants expressed 
concerns about its irreversibility, administration, and reduced contact with treatment services 
once received (Neale et al., 2018a, 2018b); these issues were not reported by the survey 
participants (Gilman et al., 2018). 
 
In terms of patients’ interest in receiving new OAT formulations, a quantitative survey of 338 
people entering inpatient opioid withdrawal management programs in the US found that 185 
(54.7%) reported that they were willing to be prescribed buprenorphine in the future and, of 
these, 48.6% said that they preferred daily oral formulations, 23.1% preferred a weekly or 
monthly injection, and 26.6% preferred a bi-annual implant (Kenney et al., 2018). Beyond this 
study, however, there has been little research exploring whether opioid users are personally 
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9 
willing to receive prolonged-release buprenorphine. Responding to this information gap, we 
undertook a qualitative interview study to ascertain opioid users’ stated willingness to receive 
depot injection buprenorphine and the factors that influenced their responses. We focused on 
the depot injection rather than the implant as the first depot buprenorphine injection was 
nearing approval for use in Europe. This gave the topic immediacy and real-world relevance. 
 
 
2. Methods 
The study was conducted in London (UK), in two community addiction treatment services, two 
hostels for homeless people, and a peer support service. The research was undertaken with 
financial support from Camurus AB, one of the developers of Buvidal and Brixadi (CAM2038). 
To the best of our knowledge, Camurus AB are the only developers of weekly and monthly 
injectable forms of depot buprenorphine. Approval to conduct the study was obtained from 
King’s College London Research Ethics Committee and separately from the participating 
services. Fieldwork took place between June and October 2018, before any form of prolonged-
release depot buprenorphine was available in Europe.  
 
To ensure that participants were all people who might be eligible for depot buprenorphine in 
the future, we purposively recruited people who were: i) using heroin daily and not receiving 
any treatment for opioid use; or ii) prescribed at least 8mg oral buprenorphine/ day; or iii) 
prescribed at least 60mg methadone/ day. To facilitate recruitment, one of the researchers 
(CT) visited the services and hostels to introduce the study to staff. Posters about the study 
were also displayed in the services. Staff liaised with keyworkers and searched electronic 
patient records to identify service users who seemed to meet the eligibility criteria. They then 
verbally outlined the study to those service users and introduced them to the researcher if they 
were interested in taking part. Of the 63 people approached by staff, 59 expressed interest.  
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10 
CT next completed a screening questionnaire with all interested individuals to check their 
eligibility and obtain demographic information (gender, age, ethnicity), details on illicit opioid 
use (age of first heroin use, current heroin use), current and previous OAT, and history of 
depot medications. Using the screening information, CT purposively sampled 12 individuals 
from each of the 3 groups (daily user of heroin, daily buprenorphine patient, daily methadone 
patient), taking care to include people with different demographic characteristics and 
medication histories. She then contacted them to arrange interviews. Despite reminders, nine 
(3 people who used heroin, 5 methadone patients, 1 buprenorphine patient) did not attend for 
interview. Three interviews were successfully re-arranged (1 person who used heroin, 2 
methadone patients), but 6 individuals could not be contacted.  
 
Prior to each interview, CT gave participants verbal and written information about the study, 
assured them of their confidentiality, and obtained written informed consent. To ensure their 
understanding, she outlined the hypothetical nature of the study and stated that depot 
buprenorphine was not currently available as a treatment in England. CT then interviewed 
each participant in private in the services using a semi-structured topic guide. This explored 
participants’ personal circumstances; their drug use and treatment history; their understanding 
of, and views on, depot buprenorphine; their personal willingness to receive depot 
buprenorphine; and factors that might alter their opinions of depot buprenorphine. To aid 
discussions, participants received basic verbal information on the concept of injectable depot 
buprenorphine, covering the potential duration, administration, dosing, and side effects (see 
Box 1). At the end of the interviews CT reminded participants that depot buprenorphine was 
not an available treatment option and that the discussions about whether they were willing to 
receive depot buprenorphine would not be interpreted beyond their early thoughts.  
 
Box 1 
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11 
Interviews were audio-recorded and lasted between 37 and 100 minutes. Participants 
received a £20 shopping voucher for taking part. Thirty-six individuals (26 men, 10 women) 
were interviewed. Participants were aged between 24 and 63 years. Most (n=23) were White 
British. Nine participants reported that they had received contraceptive medications, anti-
psychotic treatments, or testosterone replacement therapy via a depot injection in the past. 
Table 1 provides more information about the participants. 
 
Table 1 
 
All interviews were transcribed verbatim. Data coding and analyses were guided by the stages 
of Iterative Categorization (Neale, 2016). First, a coding frame was developed based on the 
interview guide and supplemented by codes emerging from the interviews. The interview 
transcriptions and the coding frame were then imported into the specialist qualitative software 
programme MaxQDA (version 11) for systematic, line-by-line coding, whereby all text was 
assigned to one or more of the codes.  
 
For this paper, data coded to the ‘personal interest in receiving depot buprenorphine’ code 
and its sub-codes (‘factors that might increase interest in receiving depot buprenorphine’ and 
‘factors that might decrease interest in receiving depot buprenorphine’) were exported into 
Microsoft Word documents and systematically reviewed to identify themes and patterns. 
During this process, any similarities and differences between sub-groups of participants were 
explored.  
 
 
3. Findings 
Early in the interviews, participants were asked if they would personally be willing to receive 
depot buprenorphine if offered it as a treatment. Participants mostly expressed a high level of 
willingness, using phrases such as ‘jump at the chance’, ‘snap it up’, and ‘be over the moon’. 
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12 
Some even said that they would be willing to receive depot buprenorphine as ‘a guinea pig’ or 
‘without the licence’. Several participants stated that they would want more information to help 
them decide, but only a few (all male) expressed a definite reluctance to try it. These included 
a participant who said that he was satisfied with his current methadone treatment and a 
participant who reported a dislike of needles and injections. Only one of the people who had 
previously received a medication via a depot injection expressed reluctance to receive depot 
buprenorphine. This man explained that although he had found receiving an anti-psychotic 
depot ‘painful’ and ‘degrading,’ his reluctance was because he liked, and was habituated to, 
the daily ritual and effects of taking oral buprenorphine. 
 
Towards the end of the interviews, participants were again asked if they would be personally 
willing to receive depot buprenorphine. There was no evidence of any participant changing 
their view, although several said that they still had questions and required more information. 
Despite their enthusiasm, analyses also revealed that participants' willingness was influenced 
both positively and negatively by six key features of depot buprenorphine: i) reduced contact 
with pharmacies and drug treatment services; ii) impact on illicit drug use and recovery; iii) the 
perceived effectiveness of depot buprenorphine; iv) the duration and dosage of depot 
buprenorphine injections; v) clinical administration of the depot buprenorphine injection; and 
vi) potential for side effects associated with the depot buprenorphine injection. These are 
described below and illustrated using pseudonymised quotations.  
 
3.1 Reduced contact with pharmacies and drug treatment services  
Patients with extensive treatment histories who reported current stability on OAT frequently 
explained that they would welcome depot buprenorphine if it reduced how often they would 
need to attend treatment services or pharmacies. Elaborating on this, they stated that 
collecting OAT from a pharmacy every day was habit-forming, time-consuming, and 
stigmatising; whereas long-acting depot buprenorphine offered them ‘freedom’ from ‘being 
chained’ or ‘tied’ to services and would be ‘easier’ and ‘more convenient’, particularly during 
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13 
times of opioid withdrawal, forgetfulness, physical ill health, and transport problems. Some 
participants also reported that depot buprenorphine could disrupt the cycle of drug-taking 
behaviours which attending services and daily supervised dosing reinforced. 
 
You get caught up going… once a week to the [drug] project [for your OAT 
prescription], every day to the doctor or the chemist, to pick it [OAT medication] up. 
Like it takes over your life, you don’t have any free time. Whereas that [weekly depot 
buprenorphine injection] sounds good, because… you’ve got seven days free until you 
have to go back [to the drug project]. (Bob, 47 years, heroin) 
 
In contrast, people who use heroin not in treatment and patients less well-established in their 
current treatment expressed concerns at the prospect of having reduced contact with 
treatment services. Their anxieties centred on losing the structure, ‘safety net,’ and emotional 
and practical support provided by visiting treatment services and by meeting with keyworkers. 
These participants reported being less willing to receive depot buprenorphine as they said that 
taking medication in isolation was ‘not enough’ to ‘recover’ and ‘only half the job’ and they 
worried that their psychosocial and other support needs would be overlooked or neglected. 
 
The important thing is how you engage back in the services again once you’ve got it 
[depot injection]… If I was on a depot, I would want someone… [to] find out exactly 
how I really am… whether I’m going to be using or not… or whether I’m alright on it… 
so you’re not falling by the wayside. (Simon, 40 years, methadone) 
 
Relatedly, a few participants emphasized that collecting OAT from a pharmacy gave opioid 
users somewhere to go, provided them with structure, enabled social interaction with 
pharmacy staff, and thereby also generally promoted recovery. They worried about losing such 
benefits if they received depot buprenorphine. 
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14 
3.2 Impact on illicit drug use and recovery 
Participants who described themselves as being motivated to stop using heroin or ‘serious’ 
about recovery said that they would be very willing to receive depot buprenorphine, stating 
that they felt certain that their drug use would cease for the duration of the injection. These 
participants reported that buprenorphine reduced cravings for, and ‘blocked’ the effects of, 
opioids; therefore, there would be ‘no point’ in using heroin anymore. Depot buprenorphine 
would, they said, help them to ‘break cycles’ of drug use and achieve stability. Moreover, it 
would enhance their opportunities to ‘get on’ and live ‘normal’ lives, which they characterised 
by work and family responsibilities rather than using illicit drugs.  
 
What’s more nicer than somebody who was a hardcore junkie can have a social life, 
can sit in a park, talk to people, can sit in the pub… If I can use that [depot 
buprenorphine] and get back a normal life, that would be clean, that would be good… 
I would love to get back into work… if that can keep you away for three or four months, 
become normal. (Earl, 54 years, heroin)  
 
Participants (particularly current buprenorphine patients who said that they had sometimes 
deliberately missed or reduced oral doses in order to use heroin and participants who stated 
that they were committed to not using heroin on top of prescribed medication) additionally 
liked the fact that depot buprenorphine injections would be harder to manipulate and 
circumvent than oral OAT formulations. However, the extended ‘blocking’ properties of depot 
buprenorphine did not appeal to all participants and led some, including those who wanted to 
continue to use heroin, to report less willingness to receive depot buprenorphine. 
 
It’s got a blocker in there that stops me from being able to use. And so once it’s done 
it’s done, there’s no taking it back… the junkie in me, the drug addict in me might be a 
little concerned because he can’t get high. (Jack, 39 years, heroin) 
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15 
3.3 The perceived effectiveness of depot buprenorphine 
Participants often emphasised that they would need to be confident that depot buprenorphine 
‘worked’ before they committed themselves to receiving it. When asked what they meant by 
‘worked’, participants said that they would need to be certain that the medication would 
guarantee them stability, prevent opioid craving and withdrawal symptoms, and block illicit 
opioids. Following on from this, some also stated that they would feel more confident that 
depot buprenorphine worked, and they would therefore be more willing to try it, if they had 
more information about the treatment or if they had spoken to other opioid users who had 
already had a depot buprenorphine injection and experienced positive outcomes.  
 
I would want to talk to somebody who has already tried it, I would, because I would 
want to listen to their experiences, i.e. did it work? That’s the main thing, did it work? 
And just because it works for you, doesn’t mean it’s going to work for me. So yeah, I 
would like to talk to somebody who’s tried it. (Darren, 53 years, heroin) 
 
Generally, participants who had themselves previously had good experiences with oral 
buprenorphine seemed more willing to try a depot injection, noting that ‘it’s still the same drug 
you’re pumping into your system, just in a different method’ (Helen, 44 years, buprenorphine). 
Furthermore, some current methadone patients and people who use heroin who had no 
personal prior experience of buprenorphine expressed interest in depot buprenorphine as they 
said that buprenorphine was a less stigmatising, less addictive, and more effective medication 
than methadone. Conversely, other participants reported a reluctance to receive depot 
buprenorphine because they had doubts about oral buprenorphine’s effectiveness and had 
heard negative reports of oral buprenorphine from other patients. In addition, methadone 
patients were sometimes worried about experiencing opioid withdrawal if they transferred from 
methadone to depot buprenorphine as they recognised that they would probably have to firstly 
reduce, and then stop current doses of methadone for a period of time to comfortably 
transition. 
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[Methadone patients] would probably be more frightened [about having depot 
buprenorphine], because it’s a known fact in users that swapping from methadone to 
buprenorphine can be painful. (Clare, 52 years, buprenorphine) 
 
3.4 Duration and dosage of depot buprenorphine injections 
Frequently, participants across all three sample groups explained how having different 
duration (weekly and monthly) depot injections and different strength dosages increased their 
personal willingness to receive depot buprenorphine because this afforded them more choice 
and flexibility in treatment. For example, participants said that they appreciated having the 
option of a shorter duration injection at start of treatment to facilitate ‘dipping your toe in gently’ 
as a ‘trial run’ to ‘see how you get on with it’ before committing to the longer monthly treatment.  
 
Something that stays in your body for 28 days, that’s a hell of a half-life that. If 
something goes wrong, that’s awful. Even seven days, that’s a hell of a half-life. Have 
a one or two-day injection… then worst case scenario you’re ill for 24 hours, but at 
least you know then that you don’t want to take the seven day one… that would 
encourage me a lot more. (Nick, 24 years, methadone) 
 
Indeed, participants (including those who had received depot medications for other conditions 
in the past) mostly viewed the idea of a monthly injection of buprenorphine as ‘daunting’ and 
‘a big step’ and expressed reluctance to ‘jump straight in’. However, they reported that they 
would be more willing to consider a monthly depot injection if they had tried out and were 
satisfied with a shorter duration depot, or if they were already accustomed to oral 
buprenorphine. Once confidence and trust in the depot buprenorphine injection had been 
established, participants said that they would prefer a longer duration depot injection as this 
would allow them more freedom from services, so enabling them to pursue their recovery and 
live a more ‘normal’ life. 
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According to many participants, again from all three sample groups, having the ability to 
transfer between depot buprenorphine injections of different durations and to ‘top up’ 
insufficient doses increased their willingness to receive depot buprenorphine. Conversely, 
concerns about depot buprenorphine injections ‘running out early’ or not lasting for the 
intended duration if not ‘topped up’ in time made them wary. In particular, participants worried 
that they would then experience opioid withdrawal but may not be believed by drug service 
staff. As a result, they would then have to use heroin in order to alleviate withdrawal, so making 
the depot injection seem pointless.  
 
I don’t want to have something that is supposed to make me feel better for a month 
and after three weeks I’m feeling rough, because it’s not, there’s no point doing it, no 
point taking it. (Jim, 46 years, buprenorphine) 
 
Some participants additionally argued that people seeking rapid detoxification from OAT may 
be less willing to having a depot injection that lasted a month because their treatment would 
be fixed for that period with no option for reduction. Others explained that the availability of 
weekly and small doses increased the appeal of depot buprenorphine for people reducing their 
dose or at the end of treatment as medications could be tapered down in small increments 
and at a pace that suited the patient. 
 
3.5 Clinical administration of depot buprenorphine injection  
Although participants were informed in the interview that the depot injection would be 
administered by a healthcare professional, participants across all three sample groups still 
emphasised that their willingness to receive depot buprenorphine would be affected by who 
administered the treatment. Thus, many explained that they would be more willing to have a 
depot buprenorphine injection if it was administered by a trained person who ‘knew what they 
were doing’. In this regard, participants mostly stated that trained medical professionals should 
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administer depot buprenorphine injections as they would know how to do this ‘properly’ (that 
is, in the ‘right place’ on the body, using ‘clean’ equipment, and with limited complications). 
Although some participants argued that hostel staff or keyworkers could be trained to 
administer depot injections, others were less certain. For example, participants who had 
received medications via depot injections in the past noted that medical professionals had 
always administered the injections.  
 
You feel safer knowing that they are medical professionals than actually if you went to 
a service and I had my keyworker administer it to me. I would have more faith and trust 
in a doctor or a nurse. (Mark, 53 years, heroin) 
 
Some participants (again across all sample groups) reported that they would be willing to 
receive depot buprenorphine if they could self-administer it. In contrast, others were against 
allowing people to self-inject the treatment, stating that the medication might be abused. In 
addition, participants sometimes suggested that people might be reluctant to receive injectable 
buprenorphine if they were afraid of needles. Despite this, participants who said that they 
personally did not like needles almost always argued that the benefits of depot buprenorphine 
outweighed any concerns they had about the administration process. 
 
3.6 Potential for side effects associated with depot buprenorphine injection  
The risk of experiencing mild or moderate side effects or reactions from the administration of 
depot buprenorphine (e.g. pain, swelling, reddening of the skin, or bruising) did not appear to 
reduce participants’ willingness to receive depot buprenorphine. Rather, most described this 
as ‘a small price to pay’ and ‘not a big deal’, noting that the longer-term benefits of the 
treatment would outweigh any short-term side effects. 
 
If the long-term goal is going to make you feel better, it’s going to give you a better 
quality of life, I think you’d accept a little bit of discomfort… If the benefit’s outweighing 
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a little bit of discomfort… I would still give it [depot buprenorphine injection] a go. 
(Andrew, 49 years, methadone) 
 
Despite this, participants generally said that prolonged side effects might deter them from 
continuing with depot buprenorphine, particularly if injected medication could not be removed 
and if no antidote was available to reverse negative reactions. Additionally, participants 
commonly explained how the risk of side effects would make them more inclined to try a 
shorter duration depot in the first instance, and to think carefully about where on their body 
they would have the injection. For example, some participants said that they would prefer to 
have the depot injection in the buttock as any complications (redness, bruising or soreness) 
would only be seen by intimate partners, whereas others expressed concern that any swelling 
or bruising on the buttock could make it painful to sit down. Others preferred different (and 
often contradictory) administration sites (arm, stomach or thigh) depending on how well they 
thought they would tolerate the injection in the particular site/s and how successfully they felt 
they would be able to cover any visible reactions.  
 
The thigh, buttock area is probably the best… if it swells, red, itching, at least it’s 
somewhere where people are not going to see… whereas if it’s on your arm it might 
stick out, unless you wore long clothes. (Tracey, 50 years, methadone) 
 
 
4. Discussion 
 
As depot buprenorphine is a very new treatment, research into the medication is developing. 
We are not aware of any published studies on patients’ experiences of receiving depot 
buprenorphine and limited research appears to have been conducted into their willingness to 
receive it. From the few studies we identified, quantitative research indicates that people who 
use opioids will be willing to receive depot buprenorphine (Gilman et al., 2018; Kenney et al., 
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2018), even though they recognize that it has both positive and negative features (Gilman et 
al., 2018). Qualitative research explored opioid users’ views of novel opioid pharmacotherapy 
delivery systems, including depot injections (Neale et al., 2018a, 2018b). Yet, such research 
was not specific to any specified medication and used focus groups to ascertain general 
insights from several people at once (Neale et al., 2018a, 2018b). In consequence, we do not 
yet know the extent to which prolonged-release depot buprenorphine genuinely constitutes a 
solution to the long-standing problem of OAT compliance. Given this apparent lack of 
information, we designed an interview study to ask potential patients to consider whether they 
would be personally willing to receive depot buprenorphine, and then explored the factors 
influencing their responses.  
 
Analyses of our interview data indicated that people prescribed daily methadone, people 
prescribed daily buprenorphine and daily users of heroin not in treatment were willing to 
receive depot buprenorphine. In accounting for this, participants frequently articulated a belief 
that depot buprenorphine injections would reduce their cravings, withdrawal symptoms, and 
use of heroin. Moreover, this would in turn enable them to pursue ‘constructive’, non-drug 
using lives characterised by reduced stigma and increased ‘normality’, ‘freedom’, and 
flexibility. Participants’ high expectations of depot buprenorphine stand in stark contrast to 
patients’ widely-reported criticisms of the inconvenience, stigma, restrictions and burden of 
taking oral OAT every day (Crawford, 2013; Fraser & valentine, 2008; Harris & McElrath, 2012; 
Neale, 2013; Neale et al., 2018b; Radcliffe & Parkes, 2013; Strike et al., 2013). Whilst this 
suggests that depot buprenorphine could potentially overcome key limitations of traditional 
OAT formulations, people may have unrealistic beliefs about, and hopes for, new medicinal 
products, particularly if they have not yet experienced the treatment and yet are eager for 
treatment or want a rapid solution to complex problems. Their views may then change if the 
new treatment fails to live up to early high expectations (Dolovich et al., 2008; Madden et al., 
2018).  
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
21 
During the interviews, participants identified features of depot buprenorphine that both 
positively and negatively influenced their willingness to receive it. Thus, they tended to be 
more willing if they believed that it would reduce the stigma and inconvenience of attending 
pharmacies and drug services; ‘block’ heroin; enhance their recovery; guarantee stability; 
prevent withdrawal; provide flexibility in terms of duration and dosage; be administered by an 
experienced medical professional in a place on their body that was painless and invisible to 
others; and not cause serious side effects. In contrast, they seemed deterred by concerns that 
psychosocial support might be removed; the medication would not be effective or would expire 
early; the injection would be administered by non-medical staff; or the treatment would 
produce irreversible or prolonged complications. Our analyses also highlighted some 
differences between participant groups; for example, depot buprenorphine seemed to be more 
attractive to individuals who were more ‘stable’ and ‘serious about not using’ illicit opioids, but 
less attractive to people who were ‘not in treatment’, ‘new to treatment’, ‘not stable in 
treatment’, or afraid of needles.  
 
Our findings are consistent with those of previous focus group research into medication 
delivery systems (Neale et al., 2018a, 2018b). This provides reassurance and increases 
trustworthiness in our current findings. Furthermore, the findings presented in this paper also 
support the argument that depot buprenorphine is a complex medication that comprises 
interacting physical, psychological and social components (Neale et al., 2018a). Thus, it 
contains a drug (buprenorphine) that potential patients considered in terms of its stigmatizing 
and addictive properties; an injection that needed to be administered by a competent 
professional (or other); and a flexible dose and duration of action. To the study participants, 
depot buprenorphine was also an unfamiliar treatment of uncertain effectiveness with 
unknown side effects that might offer them either welcome freedom from having to constantly 
attend services or unwelcome detachment from structure and psychosocial support which they 
felt they needed. Reflecting this complexity, different medication features seemed to appeal 
to particular patient subgroups (e.g. patients new to treatment were more likely to prefer 
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shorter duration injections) but also to particular individuals (e.g. participants expressed 
preferences for different administration sites). These findings highlight that willingness to 
receive a given medication is complex, individual and changeable. 
 
Our findings also connect with the wider literature about willingness to receive treatment 
medications (Alvai et al., 2015; Grebley et al., 2008; Haythornthwaite et al., 2003). For 
example, we know from existing research that stated willingness to receive a new medication 
only mediates potential use (rather than actual uptake) of the medication (Grebley et al., 2008; 
Haythornthwaite et al., 2003) and that there are different degrees of willingness to receive 
medications (Alvai et al., 2015). Indeed, high willingness is more likely to translate into uptake, 
as demonstrated in an Australian study whereby injecting drug users with hepatitis C who 
were willing to receive treatment were more likely to initiate therapy, compared to those with 
lower treatment willingness (Alvai et al., 2015). At the same time, even when people 
demonstrate high willingness to receive a medication, factors such as those stemming from 
economic, personal, provider, and social issues may play a role and influence the uptake of 
new medications (Alvai et al., 2015; Grebley et al., 2008; Haythornthwaite et al., 2003; Lubloy, 
2014). 
 
Our study has both weaknesses and strengths. None of the participants had personally been 
treated with depot buprenorphine, nor knew anyone who had received it. Although we 
ascertained willingness to receive a new treatment, this is not a marker of subsequent uptake 
and we did not explore degrees of willingness (Grebley et al., 2008; Haythornthwaite et al., 
2003). Additionally, the study took place in the community in one metropolitan area of the UK. 
This may limit the transferability of the findings to other treatment settings (e.g. residential 
treatment), other locations (e.g. countries where OAT is not available freely or that offer 
unsupervised/ take home doses of oral buprenorphine), and other people (e.g. those following 
12 step treatment approaches). Furthermore, the research was supported by funding from a 
pharmaceutical company involved in developing both weekly and monthly prolonged-release 
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buprenorphine depot injections and we used the concept of their depot injection (CAM2038) 
as a basis for the discussions. Although we emphasized our independence from the 
pharmaceutical company, the potential for social desirability reporting by participants cannot 
be ruled out.   
 
To the best of our knowledge, we conducted the first qualitative interview study on willingness 
to receive depot buprenorphine. In so doing, we generated in-depth data from a range of 
people with diverse treatment experiences who were all potentially eligible for depot 
buprenorphine. As such, our findings should be reflective of the range of views that clinicians 
will likely encounter as depot buprenorphine becomes available in practice. Our study also 
took place at a time of increased international attention into prolonged-release medications, 
so making the findings particularly topical. 
 
 
5. Conclusions  
Our analyses add to a small but emergent literature on patients’ views of prolonged-release 
buprenorphine (Gilman et al., 2018; Kenney et al., 2018). Findings support the argument that 
people are likely to welcome greater choice and flexibility in respect of OAT medications and 
delivery systems (Neale et al., 2018a, 2018b). Opioid users also seem more likely to accept 
and adhere to this new medication if it frees them from treatment services; helps them to 
reduce their illicit drug use and facilitates their recovery; is effective and does not ‘run out’; 
offers choice in terms of dose and duration; and does not have any prolonged or irreversible 
side effects. Nonetheless, reflecting earlier studies, there are aspects of daily treatment that 
some patients may be concerned about losing, such as structure, routine, and psychosocial 
support (Neale et al., 2018a). These should be carefully considered by clinicians once depot 
buprenorphine is available in treatment settings. In addition, we suggest that treatment 
providers should not assume that a patient’s early enthusiasm for depot buprenorphine 
provides a definitive reason to prescribe it. Clinicians should always offer patients appropriate 
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information and discuss all treatment options with them so that they are better able to make 
informed treatment decisions (Neale et al., 2018b; Yarborough et al., 2016). Given recent 
international approvals for the use of prolonged-release buprenorphine, qualitative and 
quantitative research is now especially needed to explore whether patients’ reported 
willingness to receive depot buprenorphine translates into actual uptake and adherence.  
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Box 1: Summary of key features of one of the depot buprenorphine formulations in 
development (CAM2038/ Buvidal®) as outlined during the interviews 
 
Overview: prolonged-release buprenorphine injection for the treatment of opioid dependence. 
 
Effectiveness: designed to help block the drug-liking effect of opioids in the brain and reduce 
withdrawal, craving, and patients’ use of illicit opioids.  
 
Duration: available as weekly and monthly depot injection. Potential to ‘top up’ dose (with 
either oral buprenorphine or a booster injection) if insufficient. Dose reductions only possible 
at end of the week/ month. Ability to transfer between weekly and monthly injections. 
 
Administration: under the skin (subcutaneous) injection by healthcare professional into 
patient’s arm, buttock, stomach, or thigh. 
 
Dosage: designed to deliver a set dose every day over weekly or monthly duration. 
 
Potential side effects: comparable to daily sublingual buprenorphine, except for mild to 
moderate injection site reactions, such as pain, itching, red skin, swelling, lump around the 
site of the injection.  
 
Service attendance: no need for supervised dosing of daily oral medications. May only have 
to attend a clinic or pharmacy on the day of the injection, either once a week or once a month.  
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Table 1: Participant demographics  
 
 
Methadone 
(n=12) 
Buprenorphine 
(n=12) 
Heroin  
(n=12) 
Total  
(n= 36) 
Gender     
Male 8 (67%) 9 (75%) 9 (75%) 26 (72%) 
Female 4 (33%) 3 (25%) 3 (25%) 10 (28%) 
     
Ethnicity     
White/ White British  10 (83%) 9 (75%) 5 (42%) 24 (67%) 
Black/ Black British 0 (0%) 2 (17%) 3 (25%) 5 (14%) 
Asian/ Asian British 1 (8%) 0 (0%) 0 (0%) 1 (3%) 
Mixed or Multiple 1 (8%) 0 (0%) 2 (17%) 3 (8%) 
Other 0 (0%) 1 (8%) 2 (17%) 3 (8%) 
     
Age (years)     
Mean (range) 40 (24-50) 47 (26-57) 47 (35-63) 45 (24-63) 
     
Current heroin use     
Yes 6 (50%) 3 (25%) 12 (100%) 21 (58%) 
No 6 (50% 9 (75%) 0 (0%) 15 (42%) 
     
Current OAT     
Methadone 12 (100%) 0 (0%) 0 (0%) 12 (33%) 
Buprenorphine 0 (0%) 12 (100%) 0 (0%) 12 (33%) 
None 0 (0%) 0 (0%) 12 (100%) 12 (33%) 
     
Time on current OAT (months)     
Mean (range) 97 (6-300) 20 (1.5-120) N/A 58 (1.5-300) 
     
Supervised consumption     
Yes 7 (58%) 7 (58%) N/A 14/24 (58%) 
No 5 (42%) 5 (42%) N/A 10/24 (42%) 
     
Frequency of pharmacy     
Daily 9 (75%) 7 (58%) N/A 16/24 (67%) 
2-3 times a week 2 (17%) 3 (25%) N/A 5/24 (21%) 
Weekly 1 (8%) 2 (17%) N/A 3/24 (13%) 
     
Ever prescribed methadone     
Yes 12 (100%) 8 (67%) 10 (83%) 27 (75%) 
No 0 (0%) 4 (33%) 2 (17%) 9 (25%) 
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Ever prescribed buprenorphine     
Yes 6 (50%) 12 (100%) 11 (92%) 29 (81%) 
No 6 (50%) 0 (0%) 1 (8%) 7 (19%) 
     
Ever received depot medication     
Yes – any 4 (33%) 2 (17%) 3 (25%) 9 (25%) 
Yes – contraception 2 (17%) 1 (8%) 2 (17%) 5 (14%) 
Yes – anti-psychotic  1 (8%) 1 (8%) 2 (17%) 4 (11%) 
Yes – other*  1 (8%) 0 (0%) 0 (0%) 1 (3%) 
No 8 (67%) 9 (75%) 9 (75%) 26 (72%) 
Don't Know 0 (0%) 1 (8%) 0 (0%) 1 (3%) 
* testosterone replacement therapy 
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